The management of hepatocellular carcinoma
The Critically Ill Cirrhotic Patient: Evaluation and Management, Page: 237-271
2019
- 1Citations
- 7Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Book Chapter Description
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality. As a tumor that predictably develops in patients with known underlying liver disease, mostly in cirrhosis, it is imperative that effective screening and surveillance strategies be implemented to identify the disease at a stage when it is curable. For early stage cirrhotic patients without prohibitive portal hypertension and with compensated liver function, surgical resection is the goal. Locoregional therapies include ablative, transarterial, and radiation-based therapies, which have a critical role in controlling the tumor, and may allow for unresectable patients with disease confined to the liver to be bridged or downstaged prior to curative-intent liver transplantation, unequivocally the gold-standard treatment for early stage patients with unresectable HCC. For locally advanced and metastatic HCC patients who are not candidates for locoregional or surgical therapy, the last few years have seen many successes with the approval of numerous targeted therapies and immunotherapies in both front line and second line. With an increasing characterization of the underlying genomic, transcriptomic, proteomic, and epigenetic aberrations that impact HCC tumor biology, there is renewed hope for the discovery of additional targeted therapies to treat tumor recurrence and allow for precision oncology approaches to patients with this deadly malignancy.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85088729336&origin=inward; http://dx.doi.org/10.1007/978-3-030-24490-3_13; http://link.springer.com/10.1007/978-3-030-24490-3_13; http://link.springer.com/content/pdf/10.1007/978-3-030-24490-3_13; https://dx.doi.org/10.1007/978-3-030-24490-3_13; https://link.springer.com/chapter/10.1007/978-3-030-24490-3_13
Springer Science and Business Media LLC
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know